Steven Martin, MD
Interventional Cardiology · Lincoln, NENPI 1023107067
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.3%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by Boston Scientific at 57.1% of the total. Among interventional cardiology clinicians in NE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 421 payments — averaging $131.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$32K
- Edwards Lifesciences$19K
- Abbott$2K
- Novartis$525
- Pfizer$357
- Amgen$313
- plus $2K from 30 others
Across 110 payments — averaging $3419.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$196K
- Currax Pharmaceuticals LLC$68K
- Boehringer Ingelheim International GmbH$31K
- Edwards Lifesciences$23K
- Boston Scientific$19K
- Pfizer$17K
- plus $23K from 2 others
What the payments were for
- Consulting fees$9,20017%
- Speaking & faculty fees$29,43653%
- Travel & lodging$7,70114%
- Food & beverage$8,91516%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 144 | $31,577 |
| Edwards Lifesciences | 89 | $18,614 |
| Abbott | 14 | $2,185 |
| Novartis | 37 | $525 |
| Pfizer | 28 | $357 |
| Amgen | 18 | $313 |
| Medtronic | 10 | $235 |
| Merck | 11 | $164 |
| E.r. Squibb & Sons, L.L.C. | 11 | $161 |
| Impulse Dynamics (USA) Inc. | 5 | $139 |
| Itamar Medical Inc | 2 | $104 |
| Johnson & Johnson | 6 | $90 |
| Abiomed | 2 | $85 |
| Sunovion Pharmaceuticals Inc. | 6 | $66 |
| Boehringer Ingelheim | 4 | $62 |
| AstraZeneca | 4 | $53 |
| Esperion Therapeutics, Inc. | 3 | $52 |
| Chiesi USA, Inc. | 3 | $51 |
| Philips North America LLC | 1 | $50 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $45 |
| Shockwave Medical, Inc | 1 | $37 |
| Baxter Healthcare | 1 | $32 |
| Novo Nordisk | 2 | $31 |
| Amarin Pharma, Inc. | 2 | $30 |
| Bridgebio Pharma, Inc. | 1 | $29 |
| Biotronik Inc. | 1 | $21 |
| Angiodynamics, Inc. | 1 | $19 |
| Heartflow, Inc. | 1 | $18 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Bard Peripheral Vascular, Inc. | 1 | $16 |
| Inspire Medical Systems, Inc. | 1 | $16 |
| Lexicon Pharmaceuticals, Inc. | 1 | $14 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $13 |
| GE HealthCare | 1 | $13 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$55,264 in reported general payments places this provider in the 90th percentile of 50 interventional cardiology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 186 | $136,956 |
| Repatha SureclickEvolocumab | 111 | $80,071 |
| XareltoRivaroxaban | 73 | $67,642 |
| EntrestoSacubitril/Valsartan | 55 | $45,852 |
| JardianceEmpagliflozin | 28 | $25,474 |
| Praluent PenAlirocumab | 24 | $24,351 |
| BrilintaTicagrelor | 14 | $12,634 |
| ClopidogrelClopidogrel Bisulfate | 403 | $3,644 |
| Metoprolol Succinate | 274 | $3,182 |
| Sildenafil Citrate | 13 | $3,085 |
| Ranolazine ErRanolazine | 25 | $2,389 |
| Amlodipine Besylate | 396 | $2,230 |
| Rosuvastatin Calcium | 196 | $2,032 |
| SotalolSotalol Hcl | 60 | $1,621 |
| Flecainide Acetate | 35 | $1,610 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $357 | $136,956186 claims |
| Johnson & JohnsonXarelto | $90 | $67,64273 claims |
| NovartisEntresto | $525 | $45,85255 claims |
| Boehringer IngelheimJardiance | $62 | $25,47428 claims |
| AstraZenecaBrilinta | $53 | $12,63414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 50 interventional cardiology providers in Nebraska.
Other interventional cardiology in Lincoln
- Brock CookmanLincoln$782K
- Matthew JohnsonLincoln$162K
- Natraj KattaLincoln$18K
- Hemantha KoduriLincoln$10K
- Denes KorpasLincoln$9K
- Harpaul BajwaLincoln$7K
- Zachary SingsankLincoln$4K
- Douglas NetzLincoln$3K
- Vishwajeth BhoopalamLincoln$3K
- Melissa AlvarezLincoln$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.